Pharmacogenetics of antipsychotic-induced weight gain: Review and clinical implications

Molecular Psychiatry

Volumn 17, Issue 3, 2012, Pages 242-266

  Lett, T A P ^a   Wallace, T J M ^a   Chowdhury, N I ^a   Tiwari, A K ^a   Kennedy, J L ^a   Muller D J ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

antipsychotics; genetics; personalized medicine; pharmacogenetics; schizophrenia; weight gain

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DEXFENFLURAMINE; ENDOCANNABINOID; FLUPHENAZINE; GHRELIN; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LEPTIN; LOW DENSITY LIPOPROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; NEUROPEPTIDE Y; NEUROTROPHIC FACTOR; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1 RECEPTOR; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TRIFLUOPERAZINE; TUMOR NECROSIS FACTOR ALPHA; ZIPRASIDONE;

DATA BASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; EPIGENETICS; GENETIC ASSOCIATION; GENETIC SCREENING; HEREDITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID METABOLISM; MEDLINE; OBESITY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDENTARY LIFESTYLE; SENSITIVITY AND SPECIFICITY; SEROTONINERGIC SYSTEM; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; APPETITE; BIOGENIC MONOAMINES; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CARDIOVASCULAR DISEASES; EPIGENESIS, GENETIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; LIPID METABOLISM; META-ANALYSIS AS TOPIC; METABOLIC SYNDROME X; NEUROTRANSMITTER AGENTS; OBESITY; PATIENT COMPLIANCE; RECEPTORS, NEUROTRANSMITTER; WEIGHT GAIN;

EID: 84857356940     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.109     Document Type: Review

References (165)

1. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010; 55: 117-125.
2. Kane JM. The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 1988; 49(Suppl): 12-14.
3. Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci 2010; 12: 345-357.
4. Müller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7: 863-887. (Pubitemid 44446736)
5. Müller DJ, Muglia P, Fortune T, Kennedy JL. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004; 49: 309-329. (Pubitemid 38175329)
6. Lencz T, Malhotra AK. Pharmacogenetics of antipsychoticinduced side effects. Dialogues Clin Neurosci 2009; 11: 405-415.
7. Himmerich H, Kaufmann C, Schuld A, Pollmacher T. Elevation of liver enzyme levels during psychopharmacological treatment is associated with weight gain. J Psychiatr Res 2005; 39: 35-42. (Pubitemid 39422284)
8. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(Suppl 1): 20-27.
9. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80: 45-53. (Pubitemid 41587462)
10. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004; 65(Suppl 18): 13-26.
11. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-246.
12. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13: 27-35. (Pubitemid 350275185)
13. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Ann Rev Med 2001; 52: 503-517. (Pubitemid 32195338)
14. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001; 158: 360-369. (Pubitemid 32205190)
15. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520. (Pubitemid 30191189)
16. Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 2010; 35: 207-211.
17. Lencz T, Correll C, Kane JM, Malhotra AK. Genome-wide association study of antipsychotic-induced weight gain in previously-untreated patients. American College of Neuropsychopharmacology 49th Meeting 2010; 49: S342.
18. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/; accessed date: 22 June 2010.
19. Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 2003; 25: 287-293. (Pubitemid 36638171)
20. Lane H-Y, Liu Y-C, Huang C-L, Chang Y-C, Wu P-L, Lu C-T et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006; 26: 128-134. (Pubitemid 43740335)
21. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25: 423-429. (Pubitemid 38981558)
22. Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 2008; 160: 308-315.
23. Lin Y-C, Ellingrod VL, Bishop JR, Miller DD. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther Drug Monit 2006; 28: 668-672. (Pubitemid 44564067)
24. de Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009; 34: 159-172.
25. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008; 40: 187-224. (Pubitemid 352000946)
26. Gentile S. Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 2009; 10: 527-542.
27. Grossman I, Sullivan PF, Walley N, Liu Y, Dawson JR, Gumbs C et al. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 2008; 10: 720-729.
28. Ghotbi R, Gomez A, Milani L, Tybring G, Syvanen AC, Bertilsson L et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 2009; 9: 208-217.
29. Travis MJ, Busatto GF, Pilowsky LS, Mulligan R, Acton PD, Gacinovic S et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br J Psychiatry 1998; 173: 236-241. (Pubitemid 28407457)
30. De Luca V, Müller DJ, Hwang R, Lieberman JA, Volavka J, Meltzer HY et al. HTR2C haplotypes and antipsychoticsinduced weight gain: X-linked multimarker analysis. Hum Psychopharmacol 2007; 22: 463-467. (Pubitemid 47611301)
31. Gunes A, Melkersson KI, Scordo MG, Dahl M-L. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009; 29: 65-68.
32. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Egberts ACG et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J 2007; 7: 318-324. (Pubitemid 47471309)
33. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007; 27: 338-343. (Pubitemid 47075503)
34. Opgen-Rhein C, Brandl EJ, Muller DJ, Neuhaus AH, Tiwari AK, Sander T et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic- induced weight gain in a German sample. Pharmacogenomics 2010; 11: 773-780.
35. Park Y-M, Cho J-H, Kang S-G, Choi J-E, Lee S-H, Kim L et al. Lack of association between the-759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 2008; 33: 55-60.
36. Popp J, Leucht S, Heres S, Steimer W. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J 2009; 9: 71-77.
37. Ryu S, Cho EY, Park T, Oh S, Jang W-S, Kim S-K et al. 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 673-677. (Pubitemid 46467047)
38. Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008; 69: 1416-1422.
39. Yevtushenko OO, Cooper SJ, O'Neill R, Doherty JK, Woodside JV, Reynolds GP. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008; 192: 424-428. (Pubitemid 351809894)
40. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998; 44: 851-864. (Pubitemid 28520223)
41. Buckland PR, Hoogendoorn B, Guy CA, Smith SK, Coleman SL, O'Donovan MC. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychoticinduced weight gain. Am J Psychiatry 2005; 162: 613-615. (Pubitemid 40343933)
42. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 2000; 43: 373-376. (Pubitemid 30163481)
43. McCarthy S, Mottagui-Tabar S, Mizuno Y, Sennblad B, Hoffstedt J, Arner P et al. Complex HTR2C linkage disequilibrium and promoter associations with body mass index and serum leptin. Human Genetics 2005; 117: 545-557. (Pubitemid 41535576)
44. Hill MJ, Reynolds GP. 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res 2007; 1149: 14-17. (Pubitemid 46661934)
45. Thorisson GA, Smith AV, Krishnan L, Stein LD. The international HapMap project web site. Genome Res 2005; 15: 1592-1593. (Pubitemid 41545013)
46. Drago A, Serretti A. Focus on HTR2C: a possible suggestion for genetic studies of complex disorders. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 601-637.
47. Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, Olajossy M, Marmurowska-Michalowska H, Limon J et al. Olanzapineinduced weight gain is associated with the-759C/T and-697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 2009; 9: 234-241.
48. Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010; 10: 20-29.
49. Gregoor JG, van derWeide J, Loovers HM, van Megen HJ, Egberts TC, Heerdink ER. Polymorphisms of the LEP-, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics 2011; e-pub ahead of print 23 April 2011.
50. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009; 29: 16-20.
51. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E et al. Regulation of serotonin-2C receptor Gprotein coupling by RNA editing. Nature 1997; 387: 303-308. (Pubitemid 27220768)
52. Iwamoto K, Bundo M, Kato T. Serotonin receptor 2C and mental disorders: genetic, expression and RNA editing studies. RNA Biol 2009; 6: 248-253.
53. Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1021-1028. (Pubitemid 41080129)
54. Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 2010; 11: 1561-1571.
55. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227-235. (Pubitemid 23091497)
56. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W et al. Brain dopamine and obesity. Lancet 2001; 357: 354-357. (Pubitemid 32128542)
57. Hong C-J, Liou Y-J, Bai YM, Chen T-T, Wang Y-C, Tsai S-J. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenetics Genomics 2010; 20: 359-366.
58. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005; 376: 1-4. (Pubitemid 40202926)
59. Himei A, Koh J, Sakai J, Inada Y, Akabame K, Yoneda H. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and-141C Ins/Del polymorphisms. Psychiatry Clin Neurosci 2002; 56: 97-102. (Pubitemid 34130626)
60. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577-582. (Pubitemid 27142107)
61. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-296. (Pubitemid 29292183)
62. Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D et al. DRD2 promoter region variation predicts antipsychoticinduced weight gain in first episode schizophrenia. Pharmacogenet Genomics 2010; 20: 569-572.
63. Müller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 2010; e-pub ahead of print 17 August 2010.
64. Comings DE, Gade R, MacMurray JP, Muhleman D, Peters WR. Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. Mol Psychiatry 1996; 1: 325-335. (Pubitemid 126441317)
65. Noble EP, Noble RE, Ritchie T, Syndulko K, Bohlman MC, Noble LA et al. D2 dopamine receptor gene and obesity. Int J Eat Disord 1994; 15: 205-217.
66. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human Mol Genet 2003; 12: 205-216. (Pubitemid 36204418)
67. Hirvonen MM, Laakso A, Na°gren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 2009; 63: 907-912.
68. Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639-651. (Pubitemid 47517514)
69. Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. Nature 1993; 365: 441-445. (Pubitemid 23311038)
70. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-614. (Pubitemid 21912282)
71. Kaplan AS, Levitan RD, Yilmaz Z, Davis C, Tharmalingam S, Kennedy JL. A DRD4/BDNF gene-gene interaction associated with maximum BMI in women with bulimia nervosa. Int J Eat Disord 2008; 41: 22-28. (Pubitemid 350308973)
72. Levitan RD, Kaplan AS, Davis C, Lam RW, Kennedy JL. A season-of-birth/DRD4 interaction predicts maximal body mass index in women with bulimia nervosa. Neuropsychopharmacology 2010; 35: 1729-1733.
73. Levitan RD, Masellis M, Lam RW, Kaplan AS, Davis C, Tharmalingam S et al. A birth-season/DRD4 gene interaction predicts weight gain and obesity in women with seasonal affective disorder: a seasonal thrifty phenotype hypothesis. Neuropsychopharmacology 2006; 31: 2498-2503. (Pubitemid 44607067)
74. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005; 30: 1374-1382. (Pubitemid 40848091)
75. Szekeres G, Keri S, Juhasz A, Rimanoczy A, Szendi I, Czimmer C et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 124B: 1-5. (Pubitemid 38031583)
76. Davis C, Levitan RD, Kaplan AS, Carter J, Reid C, Curtis C et al. Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder. Neuropsychopharmacology 2007; 32: 2199-2206. (Pubitemid 47417697)
77. LaBar KS, Cabeza R. Cognitive neuroscience of emotional memory. Nat Rev Neurosci 2006; 7: 54-64. (Pubitemid 41828931)
78. Saiz PA, Susce MT, Clark DA, Kerwin RW, Molero P, Arranz MJ et al. An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol 2008; 23: 107-114. (Pubitemid 351359582)
79. Park Y-M, Chung Y-C, Lee S-H, Lee K-J, Kim H, Byun Y-C et al. Weight gain associated with the alpha2a-adrenergic receptor-1291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 394-397. (Pubitemid 43872892)
80. Liu YR, Loh EW, Lan TH, Chen SF, Yu YH, Chang YH et al. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J 2010; 10: 30-39.
81. Sickert L, Müller DJ, Tiwari AK, Shaikh S, Zai C, De Souza R et al. Association of the alpha 2A adrenergic receptor-1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 2009; 10: 1169-1176.
82. Comuzzie AG, Allison DB. The search for human obesity genes. Science 1998; 280: 1374-1377. (Pubitemid 28264818)
83. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363. (Pubitemid 29289721)
84. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007; 104: 3456-3459. (Pubitemid 46364180)
85. Kim SH, Nikolics L, Abbasi F, Lamendola C, Link J, Reaven GM et al. Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. J Psychiatr Res 2010; 44: 493-498.
86. Jassim G, Ferno J, Theisen FM, Haberhausen M, Christoforou A, Havik B et al. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry 2011; 44: 15-20.
87. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R et al. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18: 45-48. (Pubitemid 28027877)
88. Siffert W. G-protein beta3 subunit 825T allele and hypertension. Curr Hypertens Rep 2003; 5: 47-53. (Pubitemid 38898932)
89. Hengstenberg C, Schunkert H, Mayer B, Döring A, Löwel H, Hense HW et al. Association between a polymorphism in the G protein beta3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. Cardiovasc Res 2001; 49: 820-827. (Pubitemid 32178386)
90. Dong Y, Zhu H, Sagnella GA, Carter ND, Cook DG, Cappuccio FP. Association between the C825T polymorphism of the G protein beta3-subunit gene and hypertension in blacks. Hypertension 1999; 34: 1193-1196. (Pubitemid 30002381)
91. Benjafield AV, Lin RC, Dalziel B, Gosby AK, Caterson ID, Morris BJ. G-protein beta3 subunit gene splice variant in obesity and overweight. Int J Obes Relat Metab Disord 2001; 25: 777-780. (Pubitemid 32601368)
92. Hegele RA, Anderson C, Young TK, Connelly PW. G-protein beta3 subunit gene splice variant and body fat distribution in Nunavut Inuit. Genome Res 1999; 9: 972-977. (Pubitemid 29525205)
93. SiffertW, Forster P, Jöckel KH, Mvere DA, Brinkmann B, Naber C et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999; 10: 1921-1930. (Pubitemid 29402513)
94. Rydén M, Faulds G, Hoffstedt J, Wennlund A, Arner P. Effect of the (C825T) Gbeta(3) polymorphism on adrenoceptor-mediated lipolysis in human fat cells. Diabetes 2002; 51: 1601-1608. (Pubitemid 34826631)
95. Hauner H, Meier M, Jöckel K-H, Frey UH, Siffert W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13: 453-459. (Pubitemid 37034587)
96. Hsiao D-J, Wu LS-H, Huang S-Y, Lin E. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenetics Genomics 2009; 19: 730-733.
97. Bishop JR, Ellingrod VL, Moline J, Miller D. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 2006; 12: BR47-BR50. (Pubitemid 43200936)
98. Park Y-M, Chung Y-C, Lee S-H, Lee K-J, Kim H, Choi J-E et al. G-protein beta3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients. Psychiatry Invest 2009; 6: 39-43.
99. Sudhof TC. The synaptic vesicle cycle. Ann Rev Neurosci 2004; 27: 509-547. (Pubitemid 39050412)
100. Nagamatsu S, Nakamichi Y, Yamamura C, Matsushima S, Watanabe T, Ozawa S et al. Decreased expression of t-SNARE, syntaxin 1, and SNAP-25 in pancreatic beta-cells is involved in impaired insulin secretion from diabetic GK rat islets: restoration of decreased t-SNARE proteins improves impaired insulin secretion. Diabetes 1999; 48: 2367-2373. (Pubitemid 30395428)
101. Sadoul K, Lang J, Montecucco C, Weller U, Regazzi R, Catsicas S et al. SNAP-25 is expressed in islets of Langerhans and is involved in insulin release. J Cell Biol 1995; 128: 1019-1028.
102. Jagadish MN, Fernandez CS, Hewish DR, Macaulay SL, Gough KH, Grusovin J et al. Insulin-responsive tissues contain the core complex protein SNAP-25 (synaptosomal-associated protein 25) A and B isoforms in addition to syntaxin 4 and synaptobrevins 1 and 2. Biochem J 1996; 317(Pt 3): 945-954. (Pubitemid 26308275)
103. Müller DJ, Klempan TA, De Luca V, Sicard T, Volavka J, Czobor P et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005; 379: 81-89.
104. Musil R, Spellmann I, Riedel M, Dehning S, Douhet A, Maino K et al. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res 2008; 42: 963-970.
105. Pi-Sunyer FX, Laferrere B. Metabolic abnormalities and the role of leptin in human obesity. J Clin Endocrinol Metab 1999; 84: 3-7.
106. Sentissi O, Epelbaum J, Olié J-P, Poirier M-F. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008; 34: 1189-1199.
107. Terrasi M, Fiorio E, Mercanti A, Koda M, Moncada CA, Sulkowski S et al. Functional analysis of the-2548G/A leptin gene polymorphism in breast cancer cells. Int J Cancer 2009; 125: 1038-1044.
108. Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res 2002; 34: 355-359.
109. Kang S-G, Lee H-J, Park Y-M, Choi J-E, Han C, Kim Y-K et al. Possible association between the-2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 160-163.
110. Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007; 27: 246-251. (Pubitemid 46763305)
111. Mou X-D, Zhang Z-J, Zhang X-R, Shi J-B, Sun J. 2548G/A functional polymorphism in the promoter region of leptin gene and antipsychotic agent-induced weight gain in schizophrenic patients: a study of nuclear family-based association]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008; 33: 316-320.
112. Gregoor JG, van der Weide J, Mulder H, Cohen D, van Megen HJGM, Egberts ACG et al. Polymorphisms of the LEP-and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2009; 29: 21-25.
113. Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA. Leptin gene-2548G/A variants predict risperidoneassociated weight gain in children and adolescents. Psychiatric Genet 2009; 19: 320-327.
114. Ellingrod VL, Bishop JR, Moline J, Lin Y-C, Miller DD. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull 2007; 40: 57-62.
115. Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M et al. Physiogenomic comparison of weight profiles of olanzapine-and risperidone-treated patients. Mol Psychiatry 2007; 12: 474-482. (Pubitemid 46652457)
116. List JF, Habener JF. Defective melanocortin 4 receptors in hyperphagia and morbid obesity. N Engl J Med 2003; 348: 1160-1163. (Pubitemid 36337327)
117. Farooqi IS, O'Rahilly S. Monogenic obesity in humans. Annu Rev Med 2005; 56: 443-458. (Pubitemid 40299792)
118. Dubern B, Clement K, Pelloux V, Froguel P, Girardet JP, Guy-Grand B et al. Mutational analysis of melanocortin-4 receptor, agoutirelated protein, and alpha-melanocyte-stimulating hormone genes in severely obese children. J Pediatr 2001; 139: 204-209. (Pubitemid 32721705)
119. Lubrano-Berthelier C, Cavazos M, Dubern B, Shapiro A, Stunff CL, Zhang S et al. Molecular genetics of human obesityassociated MC4R mutations. Ann NYAcad Sci 2003; 994: 49-57. (Pubitemid 36793849)
120. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008; 40: 768-775. (Pubitemid 351748863)
121. Meyre D, Delplanque J, Chevre JC, Lecoeur C, Lobbens S, Gallina S et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet 2009; 41: 157-159.
122. Eddy SR. Non-coding RNA genes and the modern RNA world. Nat Rev Genet 2001; 2: 919-929. (Pubitemid 33691089)
123. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H. BDNF function and intracellular signaling in neurons. Histol Histopathol 2010; 25: 237-258.
124. Lipska BK, Lerman DN, Khaing ZZ, Weinberger DR. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. Eur J Neurosci 2003; 18: 3097-3104. (Pubitemid 38021551)
125. Buckley PF, Mahadik S, Pillai A, Terry Jr A. Neurotrophins and schizophrenia. Schizophr Res 2007; 94: 1-11. (Pubitemid 47033973)
126. Cordeira JW, Frank L, Sena-Esteves M, Pothos EN, Rios M. Brain-derived neurotrophic factor regulates hedonic feeding by acting on the mesolimbic dopamine system. J Neurosci 2010; 30: 2533-2541.
127. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2010; e-pub ahead of print 24 August 2010.
128. Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 2007; 61: 911-922. (Pubitemid 46420580)
129. Gunstad J, Schofield P, Paul RH, Spitznagel MB, Cohen RA, Williams LM et al. BDNF Val66Met polymorphism is associated with body mass index in healthy adults. Neuropsychobiology 2006; 53: 153-156. (Pubitemid 43854175)
130. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet 2009; 41: 18-24.
131. Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN et al. BDNF levels and genotype are associated with antipsychoticinduced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008; 33: 2200-2205. (Pubitemid 351992089)
132. King PJ, Williams G, Doods H, Widdowson PS. Effect of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol 2000; 396: R1-R3. (Pubitemid 30261560)
133. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996; 380: 243-247. (Pubitemid 26090645)
134. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998; 396: 670-674.
135. Chagnon YC, Mérette C, Bouchard RH, Emond C, Roy MA, Maziade M. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004; 9: 1067-1074. (Pubitemid 40065451)
136. Chagnon YC, Bureau A, Gendron D, Bouchard RH, Merette C, Roy MA et al. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1063-1069. (Pubitemid 350207782)
137. Matias I, DiMarzo V. Endocannabinoids and the control of energy balance. Trends EndocrinolMetab 2007; 18: 27-37. (Pubitemid 44960014)
138. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825. (Pubitemid 32303781)
139. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology 2010; 35: 1315-1324.
140. Monteleone P, Milano W, Petrella C, Canestrelli B, Maj M. Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain. J Clin Psychopharmacol 2010; 30: 441-445.
141. Fern J, Skrede S, Vik-Mo AO, Ha°vik B, Steen VM. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006; 7: 69.
142. Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fernø J, Gebhardt S et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotictreated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry 2009; 14: 308-317.
143. Tiwari AK, Zai CC, Meltzer HY, Lieberman JA, Müller DJ, Kennedy JL. Association study of polymorphisms in Insulin Induced Gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Hum Psychopharmacol 2010; 25: 253-259.
144. Srivastava V, Deshpande SN, Nimgaonkar VL, Lerer B, Thelma B. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. Pharmacogenomics 2008; 9: 1055-1068.
145. Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 2008; 8: 228-236. (Pubitemid 351712647)
146. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kühn M, Schuld A et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407-418. (Pubitemid 29392689)
147. Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-409. (Pubitemid 26352672)
148. Zai G, Müller DJ, Volavka J, Czobor P, Lieberman JA, Meltzer HY et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology 2006; 188: 171-182. (Pubitemid 44371155)
149. Wang Y-C, Bai Y-M, Chen J-Y, Lin C-C, Lai I-C, Liou Y-J. Genetic association between TNFa-308 G>A polymorphism and longitudinal weight change during clozapine treatment. Hum Psychopharmacol 2010; 25: 303-309.
150. Adkins DE, Aberg K, McClay JL, Bukszar J, Zhao Z, Jia P et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2010; 16: 321-332.
151. Willer CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, Heid IM et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009; 41: 25-34.
152. Perez-Iglesias R, Mata I, Amado JA, Berja A, Garcia-Unzueta MT, Martinez Garcia O et al. Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J Clin Psychopharmacol 2010; 30: 661-666.
153. De Luca V, Müller DJ, de Bartolomeis A, Kennedy JL. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007; 10: 697-704. (Pubitemid 47517523)
154. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 2009; 43: 620-626.
155. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537-551. (Pubitemid 32735379)
156. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002; 55: 277-284. (Pubitemid 34607382)
157. McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183: 534-539. (Pubitemid 37533200)
158. Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side effects and agranulocytosis. Curr Psychiatry Rep 2011; 13: 156-165.
159. Lan TH, Loh EW, Wu MS, Hu TM, Chou P, Lan TY et al. Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics. Mol Psychiatry 2008; 13: 1129-1137.
160. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110: 103-110.
161. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696. (Pubitemid 29517559)
162. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123-136. (Pubitemid 36513927)
163. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008; 98: 47-54. (Pubitemid 350235903)
164. Herken H, Erdal M, Aydin N, Sengul C, Karadag F, Barlas O et al. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 2009; 28: 515-519.
165. Bozina N, Medved V, Kuzman MR, Sain I, Sertic J. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 2007; 21: 728-734. (Pubitemid 47437910)